Blood centers poised to boost cell and gene therapy supply chains

Blood centers have the donors, resources and community footprint that drug sponsors need to address supply chain bottlenecks for cell and gene therapies.

Cell and gene therapies such as CAR‑T and gene‑editing treatments are moving beyond cancer into autoimmune and rare‑disease indications, but their expansion is hampered by the industry’s dependence on academic medical centers for leukapheresis collection.

Shifting the first‑step cell collection to blood centers could lower costs, improve efficiency and broaden patient access, supporting the transition of both autologous and allogeneic CGTs into late‑phase development and commercial markets.